Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 TherapyXiaona Fan, Zhiwei Li, Chao Liu et al.|Frontiers in Cell and Developmental Biology|2021Cited by 65
Comparison of the Efficacy of S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Six and Eight Chemotherapy Cycles as Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer After D2 ResectionYuanyuan Yu, Guangyu Wang, Zicheng Zhang et al.|Frontiers in Oncology|2021Cited by 3